By IDSE News Staff
The FDA granted a new indication to dalbavancin (Dalvance, AbbVie) for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in pediatric patients from birth.
Dalbavancin is the first single-dose option administered as a 30-minute IV infusion for the treatment of ABSSSIs caused by designated susceptible gram-positive bacteria in pediatric patients, including infections caused by methicillin-resistant Staphylococcus aureus.